Cue Biopharma Inc (NASDAQ:CUE) has a beta value of -77.03% and has seen 169.23 shares traded in the last trading session. The company, currently valued at $52.80M, closed the last trade at $0.66 per share which meant it lost -$3.34 on the day or 0.70% during that session. The CUE stock price is -201.52% off its 52-week high price of $1.99 and 31.82% above the 52-week low of $0.45. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.26 million shares traded. The 3-month trading volume is 6.38 shares.
The consensus among analysts is that Cue Biopharma Inc (CUE) is Buy stock at the moment, with a recommendation rating of 55.84. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.13.
Cue Biopharma Inc (NASDAQ:CUE) trade information
Sporting 0.70% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CUE stock price touched $0.66 or saw a rise of 10.3%. Year-to-date, Cue Biopharma Inc shares have moved -47.71%, while the 5-day performance has seen it change 10.22%. Over the past 30 days, the shares of Cue Biopharma Inc (NASDAQ:CUE) have changed 4.64%. Short interest in the company has seen 0.77 million shares shorted with days to cover at 4.93.
Wall Street analysts have a consensus price target for the stock at $4, which means that the shares’ value could jump 83.5% from current levels. The projected low price target is $2.0 while the price target rests at a high of $7.0. In that case, then, we find that the current price level is -960.61% off the targeted high while a plunge would see the stock gain -203.03% from current levels.
Cue Biopharma Inc (CUE) estimates and forecasts
The company’s shares have lost -31.30% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -31.09%.
1 analysts offering their estimates for the company have set an average revenue estimate of 2M for the current quarter. 1 have an estimated revenue figure of 2M for the next ending quarter. Year-ago sales stood 2.66M and 3.34M respectively for this quarter and the next, and analysts expect sales will shrink by -24.76% for the current quarter and -31.09% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 20.02% 15.39% over the past 5 years. Earnings growth for 2025 is a modest 18.06% while over the next 5 years, the company’s earnings are expected to increase by 12.04%.
CUE Dividends
Cue Biopharma Inc is expected to release its next earnings report on 2025-May-12 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Cue Biopharma Inc (NASDAQ:CUE)’s Major holders
Insiders own 0.35% of the company shares, while shares held by institutions stand at 15.19% with a share float percentage of 15.24%. Investors are also buoyed by the number of investors in a company, with Cue Biopharma Inc having a total of 64.0 institutions that hold shares in the company. The top two institutional holders are BLEICHROEDER LP with over 2.86 million shares worth more than $3.55 million. As of 2024-06-30, BLEICHROEDER LP held 5.7849% of shares outstanding.
The other major institutional holder is SLATE PATH CAPITAL LP, with the holding of over 2.4 million shares as of 2024-06-30. The firm’s total holdings are worth over $2.98 million and represent 4.8567% of shares outstanding.
